Chia-Hsuan Chou
Chia-Hsuan Chou has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Hsieh Huang
Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung 83102, Taiwan
2 shared publications - Wan-Hua Tsai
Research and Development Department, GenMont Biotech Incorporation, Tainan 74144, Taiwan
2 shared publications - Yao-Tsung Yeh
Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung, Taiwan
2 shared publications - Bing-Yen Wang
Division of Thoracic Surgery, Department of Surgery, Changhua Christian Hospital, Changhua City, Taiwan
1 shared publication - Chih-Chia Huang
National Cheng Kung University
1 shared publication - Chiu-Ching Kao
Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan
1 shared publication
Latest Publications
- Open Access
- 26 November 2025
- Published by Springer Nature in Research Square
Lactobacillus protects against lead-induced hepatotoxicity by preserving the gut barrier and microbiota remodeling
Lead (Pb) toxicity is a global health concern that primarily affects the liver. This study explored the protective effects of lactobacilli against Pb(II)-induced hepatotoxicity in mice. Three strains of lactobacilli— Lacticaseibacillus paracasei GMNL-32, Limosilactobacillus fermentum GMNL-93, and Lacticaseibacillus casei GMNL-277—were evaluated for Pb adsorption and cytoprotective properties. The results indicated that probiotic treatment reduced the liver-to-body weight ratio, aspartate transaminase and alanine transaminase levels, and liver damage without increasing Pb excretion. It also upregulated the expression of gut tight junction proteins, reduced the levels of inflammatory cytokines (tumor necrosis factor-α and interleukin-6), and modulated the diversity and composition of the gut microbiota. Strong correlations were observed between probiotics, microbial abundance, metabolic pathways, and reduced liver inflammation. Overall, this study suggests that GMNL-32, GMNL-93, and GMNL-277 can mitigate Pb-induced hepatotoxicity by modulating the gut microbiota and regulating metabolism. Thus, these probiotics hold promise as protective agents against Pb-induced hepatotoxicity.
- 26 November 2025
- Published by Springer Nature in Research Square
Open AccessLactobacillus protects against lead-induced hepatotoxicity by preserving the gut barrier and microbiota remodeling
Lead (Pb) toxicity is a global health concern that primarily affects the liver. This study explored the protective effects of lactobacilli against Pb(II)-induced hepatotoxicity in mice. Three strains of lactobacilli— Lacticaseibacillus paracasei GMNL-32, Limosilactobacillus fermentum GMNL-93, and Lacticaseibacillus casei GMNL-277—were evaluated for Pb adsorption and cytoprotective properties. The results indicated that probiotic treatment reduced the liver-to-body weight ratio, aspartate transaminase and alanine transaminase levels, and liver damage without increasing Pb excretion. It also upregulated the expression of gut tight junction proteins, reduced the levels of inflammatory cytokines (tumor necrosis factor-α and interleukin-6), and modulated the diversity and composition of the gut microbiota. Strong correlations were observed between probiotics, microbial abundance, metabolic pathways, and reduced liver inflammation. Overall, this study suggests that GMNL-32, GMNL-93, and GMNL-277 can mitigate Pb-induced hepatotoxicity by modulating the gut microbiota and regulating metabolism. Thus, these probiotics hold promise as protective agents against Pb-induced hepatotoxicity.
- Open Access
- 12 June 2024
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 17 (5) , 3416-3428
A Lactobacillus Combination Ameliorates Lung Inflammation in an Elastase/LPS—induced Mouse Model of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is the world's leading lung disease and lacks effective and specific clinical strategies. Probiotics are increasingly used to support the improvement of the course of inflammatory diseases. In this study, we evaluated the potential of a lactic acid bacteria (LAB) combination containing Limosilactobacillus reuteri GMNL-89 and Lacticaseibacillus paracasei GMNL-133 to decrease lung inflammation and emphysema in a COPD mouse model. This model was induced by intranasal stimulation with elastase and LPS for 4 weeks, followed by 2 weeks of oral LAB administration. The results showed that the LAB combination decreased lung emphysema and reduced inflammatory cytokines (IL-1β, IL-6, TNF-α) in the lung tissue of COPD mice. Microbiome analysis revealed that Bifidobacterium and Akkermansia muciniphila, reduced in the gut of COPD mice, could be restored after LAB treatment. Microbial α-diversity in the lungs decreased in COPD mice but was reversed after LAB administration, which also increased the relative abundance of Candidatus arthromitus in the gut and decreased Burkholderia in the lungs. Furthermore, LAB-treated COPD mice exhibited increased levels of short-chain fatty acids, specifically acetic acid and propionic acid, in the cecum. Additionally, pulmonary emphysema and inflammation negatively correlated with C. arthromitus and Adlercreutzia levels. In conclusion, the combination of L. reuteri GMNL-89 and L. paracasei GMNL-133 demonstrates beneficial effects on pulmonary emphysema and inflammation in experimental COPD mice, correlating with changes in gut and lung microbiota, and providing a potential strategy for future adjuvant therapy.
- 12 June 2024
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 17 (5) , 3416-3428
Open AccessA Lactobacillus Combination Ameliorates Lung Inflammation in an Elastase/LPS—induced Mouse Model of Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is the world's leading lung disease and lacks effective and specific clinical strategies. Probiotics are increasingly used to support the improvement of the course of inflammatory diseases. In this study, we evaluated the potential of a lactic acid bacteria (LAB) combination containing Limosilactobacillus reuteri GMNL-89 and Lacticaseibacillus paracasei GMNL-133 to decrease lung inflammation and emphysema in a COPD mouse model. This model was induced by intranasal stimulation with elastase and LPS for 4 weeks, followed by 2 weeks of oral LAB administration. The results showed that the LAB combination decreased lung emphysema and reduced inflammatory cytokines (IL-1β, IL-6, TNF-α) in the lung tissue of COPD mice. Microbiome analysis revealed that Bifidobacterium and Akkermansia muciniphila, reduced in the gut of COPD mice, could be restored after LAB treatment. Microbial α-diversity in the lungs decreased in COPD mice but was reversed after LAB administration, which also increased the relative abundance of Candidatus arthromitus in the gut and decreased Burkholderia in the lungs. Furthermore, LAB-treated COPD mice exhibited increased levels of short-chain fatty acids, specifically acetic acid and propionic acid, in the cecum. Additionally, pulmonary emphysema and inflammation negatively correlated with C. arthromitus and Adlercreutzia levels. In conclusion, the combination of L. reuteri GMNL-89 and L. paracasei GMNL-133 demonstrates beneficial effects on pulmonary emphysema and inflammation in experimental COPD mice, correlating with changes in gut and lung microbiota, and providing a potential strategy for future adjuvant therapy.
- Open Access
- 12 July 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (7) , 1028
Progenitor Cells Derived from Drain Waste Product of Open-Heart Surgery in Children
Human cardiac progenitor cells isolated from the same host may have advantages over other sources of stem cells. The aim of this study is to establish a new source of human progenitor cells collected from a waste product, pericardiac effusion fluid, after open-heart surgery in children with congenital heart diseases. The fluid was collected every 24 h for 2 days after surgery in 37 children. Mononuclear cells were isolated and expanded in vitro. These pericardial effusion-derived progenitor cells (PEPCs) exhibiting cardiogenic lineage markers, were highly proliferative and enhanced angiogenesis in vitro. Three weeks after stem cell transplantation into the ischemic heart in mice, cardiac ejection fraction was improved significantly without detectable progenitor cells. Gene expression profiles of the repaired hearts revealed activation of several known repair mechanisms including paracrine effects, cell migration, and angiogenesis. These progenitor cells may have the potential for heart regeneration.
- 12 July 2019
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (7) , 1028
Open AccessProgenitor Cells Derived from Drain Waste Product of Open-Heart Surgery in Children
Human cardiac progenitor cells isolated from the same host may have advantages over other sources of stem cells. The aim of this study is to establish a new source of human progenitor cells collected from a waste product, pericardiac effusion fluid, after open-heart surgery in children with congenital heart diseases. The fluid was collected every 24 h for 2 days after surgery in 37 children. Mononuclear cells were isolated and expanded in vitro. These pericardial effusion-derived progenitor cells (PEPCs) exhibiting cardiogenic lineage markers, were highly proliferative and enhanced angiogenesis in vitro. Three weeks after stem cell transplantation into the ischemic heart in mice, cardiac ejection fraction was improved significantly without detectable progenitor cells. Gene expression profiles of the repaired hearts revealed activation of several known repair mechanisms including paracrine effects, cell migration, and angiogenesis. These progenitor cells may have the potential for heart regeneration.